|Chemical and physical data|
|Molar mass||228.117 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.
As of March 2008, Dov had no intention to further develop DOV-216,303 because the patent on the compound had expired.:6
- McCoy, Michael (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". C&EN.
- "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008.
DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
- "DOV 216303". AdisInsight. Retrieved 26 February 2017.
- Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. (2006). "Preclinical and Clinical Pharmacology of DOV 216,303, a "Triple" Reuptake Inhibitor". CNS Drug Reviews. 12 (2): 123–134. doi:10.1111/j.1527-3458.2006.00123.x. PMID 16958986.
- Chu, Tak-Ho; Cummins, Karen; Stys, Peter K. (2018). "The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice". Neuroscience Letters. 675: 1–6. doi:10.1016/j.neulet.2018.03.050. ISSN 0304-3940. PMID 29578004.